Lung Neoplasms

The grounding supports smoking as a relevant mechanism associated with lung neoplasms. It also supports genetic and molecular alterations in lung cancer, including changes involving receptor tyrosine kinases, ErbB receptors, and RAS/MAPK signaling, but does not provide a complete causal aetiology.

The literature grounding points to dysregulated signal transduction, gene expression regulation, cell proliferation, and transcriptome changes in lung cancer. It also highlights tumor microenvironment effects, immune interactions such as PD-1/PD-L1 biology and tumor-infiltrating lymphocytes, and acquired drug resistance as key biological features.

Smoking is explicitly supported as a risk-associated mechanism in the grounding. The supplied material also indicates that specific molecular alterations and tumor heterogeneity are important in lung cancer biology, but it does not support a broader list of epidemiologic risk factors.

Management is described at the level of surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The grounding specifically supports platinum-based chemotherapy, taxanes, pemetrexed, camptothecin-class therapy, EGFR-targeted agents, and immune checkpoint inhibitors such as PD-1/PD-L1-directed therapies, with treatment selection informed by biomarkers.